Evidence map›Paper›PMID 38813483›Full record

ArticleTurkish journal of medical sciences2023

COVID-19 in cancer patients: patient characteristics and outcomes in the post-COVID-19 vaccination period.

Gülşen Iskender, Duygu Mert, Göknur Yapar Toros, Funda Yilmaz, Ersin Bozan, Semra Tunçbilek, Ömür Berna Çakmak Öksüzoğlu, Fevzi Altuntaş, Mustafa Ertek

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gülşen IskenderDepartment, of Infectious Diseases and Clinical Microbiology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkiye.ORCID https://orcid.org/0000-0001-7619-1366
Duygu MertDepartment, of Infectious Diseases and Clinical Microbiology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-6810-2199
Göknur Yapar TorosDepartment of Infectious Diseases and Clinical microbiology, Ankara Etlik City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0001-8256-0666
Funda YilmazDivision of Medical Oncology, Erzurum City Hospital, Erzurum, Turkiye.ORCID https://orcid.org/0000-0002-7409-5730
Ersin BozanDepartment of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-3307-3121
Semra TunçbilekDepartment, of Infectious Diseases and Clinical Microbiology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-8860-5738
Ömür Berna Çakmak ÖksüzoğluDepartment of Medical Oncology, University of Health Sciences, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-2756-8646
Fevzi AltuntaşDepartment of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkiye.ORCID https://orcid.org/0000-0001-6872-3780
Mustafa ErtekDepartment, of Infectious Diseases and Clinical Microbiology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-9397-8432

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: It wasaimed herein to investigate coronavirus disease (COVID-19) in cancer patients and compare hematological and solid organ cancer patients in terms of the course and outcome of this disease. Materials and methods: Data from cancer patients with laboratory-confirmed COVID-19 infection were analyzed retrospectively. Risk factors for poor prognosis and the effect of vaccination on the clinical outcomes of the patients were evaluated. Results: A total of 403 cancer patients who were diagnosed with COVID-19 between March 1st, 2021, and November 30th, 2022, were included, of whom 329 (81.6%) had solid and 74 (18.4%) had hematological cancers. Hospitalization and intensive care unit (ICU) admission rates were significantly higher in the hematological cancer patients compared to the solid organ cancer patients (73.0% vs. 35.9%, p< 0.001 and 25.7% vs. 14.0%, p= 0.013, respectively). The COVID-19 Conclusion: This study revealed that there is an increased risk of COVID-19-related serious events (hospitalization, ICU admission, or death) in patients with hematological cancerscompared with those who have solid organ cancers. It wasalso shown that receiving ≥3 doses of COVID-19 vaccine is more protective against severe illness and the need for hospitalization than ≤2 doses.

Indexed as

COVID-19COVID-19 VaccinesHospitalizationNeoplasmsAdultAgedFemaleHumansIntensive Care UnitsMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsSARS-CoV-2VaccinationCOVID-19 VaccinesCancer patientsCOVID-19COVID-19 vaccination

Identifiers

PMID38813483
PMCPMC10760596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.